Interim report January – March 2007

• Net sales in the first quarter amounted to 118.9 (120.6) MSEK. At comparable exchange rates sales increased by 5%.

• The operating result for the first quarter amounted to 7.2 (-12.2) MSEK.

• The net result for the first quarter amounted to 7.2 (-20.8) MSEK and the result per share to 0.08 (-0.24) SEK.

• The cash flow from operating activities amounted to 14.2 (-11.6) MSEK.

• Net sales in the last 12 months amounted to 517.8 MSEK and the operating result to 25.9 MSEK.

• At the end of March the company introduced two new products at the congress of the ACS, the American Chemical Society, in Chicago; a new, modified system for evaporation, V10 and SNAP, a newly developed series of consumables for purification, which were both received positively.

• McMaster University and Biotage have signed an agreement regarding the development of a new chemistry platform which will enable a more efficient production within the areas of molecular imaging and therapy agents. These areas address new markets of interest to Biotage with the existing product portfolio.

• In accordance with authorization from the Annual General Meeting on April 27, 2006 a global share option program for the Group’s employees was approved.